PubMed
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging (FOXO4-DRI)
Baar et al., 2017
Longevity & Anti-AgingResearch OnlyS
FOXO4-DRI
Senolytic Peptide FOXO4
FOXO4-DRI is a D-amino acid retro-inverso (DRI) peptide designed to disrupt the interaction between the FOXO4 transcription factor and p53 protein that keeps senescent cells (zombie cells) alive. Published mouse studies (Nature 2017) showed that FOXO4-DRI selectively induced apoptosis of senescent cells, improving fitness, coat density, and kidney function. No human clinical trials have been published. Research only; handle with caution.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 3
- Research grade
- S
- Community score
- 173
- Trackers
- 3,194
Trend index
Overview
About FOXO4-DRI
FOXO4-DRI is a D-amino acid retro-inverso (DRI) peptide designed to disrupt the interaction between the FOXO4 transcription factor and p53 protein that keeps senescent cells (zombie cells) alive. Published mouse studies (Nature 2017) showed that FOXO4-DRI selectively induced apoptosis of senescent cells, improving fitness, coat density, and kidney function. No human clinical trials have been published. Research only; handle with caution.
- Category
- Longevity & Anti-Aging
- Regulatory status
- Research Only
- Also known as
- Senolytic Peptide FOXO4
- Self-reports
- 28
Community
What 28 users report
28 community reports
Positive 97% · Neutral 3% · Negative 0%
Most reported benefits
Recovery
178
Energy
178
Dose distribution
Median: 2000+ mcg · Most common: 2000+ mcg
0–25
0
25–50
0
50–100
0
100–200
0
200–400
0
400–600
0
600–1000
0
1000–2000
58
2000+
120
Commonly stacked with
How repeat users are trending
Among repeat reporters, 88% said they felt similar to their last entry, 12% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 194 days · Based on 26 repeat reporters
Research
Cited research (1)
Source
Help
Frequently asked
What do PeptIQ users report about FOXO4-DRI?
This page summarizes 28 anonymized self-reports from PeptIQ users who track FOXO4-DRI, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
What research is cited for FOXO4-DRI?
1 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is FOXO4-DRI safe to use?
This wiki does not assess safety or recommend use. FOXO4-DRI is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of FOXO4-DRI?
Research, primarily in animal models, suggests FOXO4-DRI may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of FOXO4-DRI?
FOXO4-DRI is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified FOXO4-DRI as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of FOXO4-DRI?
The safety and effectiveness of FOXO4-DRI have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on FOXO4-DRI?
While there are over 200 published studies on FOXO4-DRI, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source